AR084217A1 - Inhibidores macrociclicos de virus flaviviridae - Google Patents
Inhibidores macrociclicos de virus flaviviridaeInfo
- Publication number
- AR084217A1 AR084217A1 ARP110104596A ARP110104596A AR084217A1 AR 084217 A1 AR084217 A1 AR 084217A1 AR P110104596 A ARP110104596 A AR P110104596A AR P110104596 A ARP110104596 A AR P110104596A AR 084217 A1 AR084217 A1 AR 084217A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- nhc
- alkynyl
- alkenyl
- Prior art date
Links
- 241000710781 Flaviviridae Species 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000004419 alkynylene group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42207110P | 2010-12-10 | 2010-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084217A1 true AR084217A1 (es) | 2013-05-02 |
Family
ID=45464097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104596A AR084217A1 (es) | 2010-12-10 | 2011-12-07 | Inhibidores macrociclicos de virus flaviviridae |
Country Status (20)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PL2861604T3 (pl) | 2012-06-08 | 2017-08-31 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
| EA201492205A1 (ru) | 2012-06-08 | 2015-10-30 | Джилид Сайэнс, Инк. | Макроциклические ингибиторы вирусов flaviviridae |
| MX2016008452A (es) * | 2013-12-23 | 2016-10-14 | Gilead Sciences Inc | Sintesis de un tripeptido macrociclico inhibidor de ns3 de virus de la hepatitis c. |
| CA2960436C (en) | 2014-09-16 | 2021-01-05 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
| MY188211A (en) | 2015-03-04 | 2021-11-24 | Gilead Sciences Inc | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| JP2018525412A (ja) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | 重水素化トール様受容体調節因子 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109414508A (zh) | 2016-05-27 | 2019-03-01 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| MA46093A (fr) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| FI3526323T3 (fi) | 2016-10-14 | 2023-06-06 | Prec Biosciences Inc | Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| JP6934562B2 (ja) | 2017-08-22 | 2021-09-15 | ギリアード サイエンシーズ， インコーポレイテッド | 治療用複素環式化合物 |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PL3820572T3 (pl) | 2018-07-13 | 2024-02-26 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CA3117199C (en) | 2018-10-24 | 2024-03-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR102808642B1 (ko) | 2019-03-07 | 2025-05-14 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| SI4037708T1 (sl) | 2019-09-30 | 2025-01-31 | Gilead Sciences, Inc. | Cepiva proti hbv in postopki zdravljenja hbv |
| IL320513A (en) | 2019-11-04 | 2025-06-01 | Revolution Medicines Inc | RAS inhibitors |
| US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
| CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP7712352B2 (ja) | 2020-08-07 | 2025-07-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用 |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN114796193B (zh) * | 2022-05-13 | 2023-07-18 | 黑龙江八一农垦大学 | 抗牛病毒性腹泻病毒的中药单体 |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| CN101242842A (zh) * | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
-
2011
- 2011-12-07 UY UY0001033775A patent/UY33775A/es not_active Application Discontinuation
- 2011-12-07 AR ARP110104596A patent/AR084217A1/es unknown
- 2011-12-08 NZ NZ612159A patent/NZ612159A/en not_active IP Right Cessation
- 2011-12-08 ES ES11805697.7T patent/ES2536321T3/es active Active
- 2011-12-08 EP EP11805697.7A patent/EP2649076B1/en active Active
- 2011-12-08 PL PL11805697T patent/PL2649076T3/pl unknown
- 2011-12-08 WO PCT/US2011/064009 patent/WO2012078915A1/en not_active Ceased
- 2011-12-08 CN CN201180066396.4A patent/CN103403009B/zh not_active Expired - Fee Related
- 2011-12-08 PT PT118056977T patent/PT2649076E/pt unknown
- 2011-12-08 JP JP2013543356A patent/JP5847193B2/ja not_active Expired - Fee Related
- 2011-12-08 MX MX2013006475A patent/MX2013006475A/es active IP Right Grant
- 2011-12-08 US US13/315,069 patent/US8513184B2/en not_active Expired - Fee Related
- 2011-12-08 CA CA2819824A patent/CA2819824A1/en not_active Abandoned
- 2011-12-08 AU AU2011338262A patent/AU2011338262B2/en not_active Ceased
- 2011-12-08 EA EA201390822A patent/EA026114B1/ru not_active IP Right Cessation
- 2011-12-08 KR KR1020137017607A patent/KR20140031841A/ko not_active Abandoned
- 2011-12-08 SI SI201130434T patent/SI2649076T1/sl unknown
- 2011-12-08 BR BR112013014063A patent/BR112013014063A2/pt not_active IP Right Cessation
- 2011-12-09 TW TW100145540A patent/TWI520966B/zh not_active IP Right Cessation
-
2013
- 2013-06-04 IL IL226739A patent/IL226739A/en active IP Right Grant
- 2013-07-15 US US13/942,501 patent/US8933015B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT2649076E (pt) | 2015-06-02 |
| JP5847193B2 (ja) | 2016-01-20 |
| EA201390822A1 (ru) | 2013-12-30 |
| JP2014503516A (ja) | 2014-02-13 |
| CN103403009B (zh) | 2016-01-13 |
| CA2819824A1 (en) | 2012-06-14 |
| PL2649076T3 (pl) | 2015-08-31 |
| NZ612159A (en) | 2015-07-31 |
| BR112013014063A2 (pt) | 2016-09-13 |
| TW201307355A (zh) | 2013-02-16 |
| CN103403009A (zh) | 2013-11-20 |
| EA026114B1 (ru) | 2017-03-31 |
| UY33775A (es) | 2012-07-31 |
| IL226739A (en) | 2017-05-29 |
| US8933015B2 (en) | 2015-01-13 |
| US8513184B2 (en) | 2013-08-20 |
| ES2536321T3 (es) | 2015-05-22 |
| AU2011338262B2 (en) | 2016-12-15 |
| MX2013006475A (es) | 2013-11-01 |
| US20140023616A1 (en) | 2014-01-23 |
| US20130022573A1 (en) | 2013-01-24 |
| WO2012078915A1 (en) | 2012-06-14 |
| EP2649076B1 (en) | 2015-03-04 |
| AU2011338262A1 (en) | 2013-07-11 |
| TWI520966B (zh) | 2016-02-11 |
| HK1191000A1 (en) | 2014-07-18 |
| SI2649076T1 (sl) | 2015-07-31 |
| KR20140031841A (ko) | 2014-03-13 |
| EP2649076A1 (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084217A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR055395A1 (es) | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c | |
| AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| HRP20241482T1 (hr) | Kratki peptidni spoj prolina s modificiranim prstenom i njegova uporaba | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR071395A1 (es) | Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral | |
| AR051248A1 (es) | Derivados de 3-arilamino piridina | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR080433A1 (es) | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. | |
| AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
| AR056327A1 (es) | Compuestos de nucleosidos para el tratamiento de infecciones virales | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| RU2013124812A (ru) | Зонд, визуализирующий белок тау |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |